Apricus Biosciences (APRI) Posts Q4 Loss of 40c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apricus Biosciences Provides Corporate Update and 2014 Year-End Financial Results
March 16, 2015 7:01 AM EDTSAN DIEGO, March 16, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and year ended December 31, 2014 and provided a corporate update and its clinical development and commercialization plans for 2015.
"In 2014, our overarching objective was to build Apricus into a development stage biopharmaceutical company with a diversified product pipeline with the potential to build meaningful long-term shareholder value," stated Richard Pascoe, Chief Executive Officer. "We successfully accomplished that objective with the in-licensing of fispemifene, a Phase 2... More
Apricus Biosciences Provides Corporate Update and 2014 Year-End Financial Results
March 16, 2015 7:00 AM EDTSAN DIEGO, March 16, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and year ended December 31, 2014 and provided a corporate update and its clinical development and commercialization plans for 2015.
"In 2014, our overarching objective was to build Apricus into a development stage biopharmaceutical company with a diversified product pipeline with the potential to build meaningful long-term shareholder value," stated Richard Pascoe, Chief Executive Officer. "We successfully accomplished that objective with the in-licensing of fispemifene, a Phase 2... More
